ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper

Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using fractional flow reserve (FFR). Based on costs from the DEFINE-FLAIR trial, researchers estimate the difference to be almost USD 1000.

This should not be seen as good news for any given technology (iFR, in this case), but for physiologic assessment as a general concept. Many more interventional cardiologists need to start using physiologic assessment as a standard course of action in their cath labs, because there is much evidence that it improves outcomes.

 

FFR requires maximum hyperemia, which is achieved by using adenosine—with its associated side effects and costs. On the other hand, iFR calculates the pressure gradient of a lesion during diastole, immediately after the dicrotic wave, when physiologic resistance is minimum. That renders unnecessary the use of hyperemic agents.


Read also: NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising.


Last year, DEFINE-FLAIR and iFR-SWEDEHEART results proved the noninferiority of iFR in terms of events compared with FFR measurement.

 

The difference in terms of costs is driven by the fact that FFR-guided procedures identified more significant lesions that required treatment. More time must go by for the assessment of this aspect. If, in the future, some lesions left untreated with iFR require reintervention, the equation might be inverted by the late catch-up phenomenon. The opposite might also turn out to be true: less stenting with iFR might derive in less restenosis and less future thrombosis.

 

Original title: Comparative Cost-Effectiveness of the Instantaneous Wave-Free Ratio Versus Fractional Flow Reserve in Coronary Revascularization Decision-Making.

Presenter: Patel MR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...

CRT 2026 | Clopidogrel vs Aspirin as Long-Term Monotherapy After Coronary Angioplasty

The use of aspirin as chronic antiplatelet therapy after percutaneous coronary intervention (PCI) has historically been the standard recommended by international guidelines. However, recent...

Bioresorbable devices vs DES in patients at high risk of restenosis. Seven-year follow-up of the COMPARE-ABSORB trial

Studies with second-generation drug-eluting stents (DES) have shown that the rate of target lesion failure (TLF) increases linearly up to 5–10 years of follow-up,...

Sheathless Femoral Impella: A New Strategy to Reduce Vascular Complications in High-Risk PCI?

Patients with complex coronary artery disease or cardiogenic shock undergoing percutaneous coronary intervention (PCI) may benefit from the hemodynamic support provided by percutaneous ventricular...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

CRT 2026 | TAVI-CLOSE Trial: Dual Suture vs Suture + Plug for Vascular Closure After Transfemoral TAVI

The transfemoral approach is the predominant strategy for transcatheter aortic valve implantation (TAVI). Although vascular complications are currently less frequent, they remain relevant determinants...

CRT 2026 | NAVITOR IDE: Hemodynamic Outcomes and 5-Year Durability of an Intra-Annular Self-Expanding Transcatheter Aortic Valve

As TAVI expands into younger populations and patients with lower surgical risk, prosthesis durability has become a key aspect of long-term management. The NAVITOR...

CRT 2026 | CUT-DRESS Trial: Lesion Preparation with Cutting Balloon

In-stent restenosis (ISR) continues to represent a relevant clinical challenge in contemporary coronary angioplasty practice. Despite advances in drug-eluting stents, neointimal hyperplasia and suboptimal...